- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06027697
Prospective Evaluation of Subchondroplasty in Advanced Knee Osteoarthritis.
The goal of this observational study is to evaluate the technique of subchondroplasty in patients with advanced knee osteoarthritis.
The main question it aims to answer is:
• Does the subchondroplasty technique with the administration of AccuFill Porous Bone Substitute Material (BSM) is effective in the relief of mechanical pain in patient with knee osteoarthritis ?
Participants will go under a minimally invasive surgery procedure (subchondroplasty) and fulfil 3 validated questionnaires to assess pain, functional impairments and subjective improvement.
This study will be conducted for 4 years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background :
The technique of subchondroplasty is recent and was created to follow the availability of low-viscosity injectable phosphocalcic cement. It is aimed at osteoarthritic lesions and proposes to treat subchondral disease associated with the process of osteoarthritic degeneration, and which would be particularly painful in the support area.
This technique seems interesting in terms of effectiveness with less risk since it is a minimally invasive percutaneous procedure and it is systematically practiced on an outpatient basis.
In this context, the principal investigator has decided to conduct a long-term study for the first time in France in order to collect clinical data and data on the safety profile of the device.
Design :
This study is prospective, longitudinal, observational, single-arm, open monocentric and is a post-market study.
Intervention :
As the current study is observational, the study will follow the usual standard of care.
The participation of the patient can be divided in 2 parts :
- The first part is the treatment. After the inclusion of the patient, this latest will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the treatment (AccuFill Porous Bone Substitute Material (BSM)).
- The second part is the follow-up visits. During this part the patient will follow a appointment schedule with the doctor in order for the physicien to realised a clinical examination and for the patient to fulfil the 3 validated questionnaires. These visits will be spaced out over 4 years.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Guy Mylle, Dr
- Phone Number: 01 44 01 01 02
- Email: guymylle@gmail.com
Study Locations
-
-
-
Charenton-le-Pont, France, 94220
- Clinique Paris Bercy
-
Principal Investigator:
- Guy Mylle, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient 18 years of age or older;
- Patient with a Body Mass Index ≤35 (BMI=kg/m2);
- Patient with Kellgren-Lawrence grade 3-4 Osteoarthritis, as reviewed on MRI and plain radiography;
- Patient with knee bone marrow lesions confirmed by MRI result at least 3 months before the intervention;
- Patients with degenerative knee pathology at the prosthetic stage (outdated medical treatments), with a frontal deformity of less than 12°, (and wishing to avoid or delay the prosthetic procedure as much as possible) / goniometry);
- Patient with unbearable mechanical pain with a walking perimeter limited at 500 m
- Patient with non-surgical treatment failure (infiltration of Platelet Rich Plasma (PRP), corticoids, acid hyaluronic);
- Patient who agrees to participate in the study and who signed the informed non-opposition form;
- Patient physically and mentally willing and able, in the Investigator's opinion at the time of enrolment, to be compliant with the protocol including all follow-up visits, survey completion, weight- bearing restrictions, and post-operative rehabilitation;
- Patient with social protection.
Exclusion Criteria:
- Patient with a Body Mass Index > 35 (BMI=kg/m2);
- Patient with inflammatory rheumatic pathologies;
- Patient with frontal deformities (varus, valgus) of more than 12°;
- Patient with degenerative pathologies at the operative stage but likely to benefit from a conservative intervention (osteotomy), except if the knee is centred;
- Patient with stiff knees (more than 20° of flexum and/or less than 90° of flexion);
- Patient with painful severe femoro-patellar osteoarthritis;
- Patient with contraindications for Magnetic Resonance Imaging (MRI);
- Patient with history of systemic diseases which could contribute to secondary arthropathies (e.g., sickle cell disease, hemochromatosis, or autoimmune disease);
- Patient with history of cognitive-behavioural disorders that could interact with assessment by self-questionnaire;
- Patient with local or general infection or suspicion of infection;
- Patient with severe coagulation disorders;
- Patient with primary bone tumour in the knee area,
- Patient with undercurrent serious pathology with life expectance < 2 years;
- Female patient of childbearing age that are known to be pregnant during inclusion visit or wishing to become pregnant before treatment;
- Patient who has forfeited their freedom by administrative or legal award, or is under guardianship or under limited judicial protection;
- Patient participating in another interventional clinical trial or testing an experimental drug within 30 days of inclusion in the study;
- Patients who cannot read or write French
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subchondroplasty
AccuFill Porous Bone Substitute Material (BSM) will be administrated to the patient during a subchondroplasty procedure (treatment visit). During the inclusion visit and the follow-up visits (Week 3, Week 6; Month 3, Month 6, Month 12, Month 24, Month 36, Month 48) the doctor will proceed the usual clinical exam and the patients will fulfil the validated questionnaires and scales to assess pain, functional impairments and subjective improvement. |
The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (inclusion) in Patient-Reported Pain Scores on the Visual Analog Scale (VAS) to 3 months.
Time Frame: Month 3
|
Visual Analog Scale (VAS) is a unidimensional measure of pain intensity, used to record patients' pain progression.
It will helped the patient to assess the perceived mechanical knee pain on a horizontal, non-calibrated line of 10 cm, ranging from very low (0) to very high (10)
|
Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline (inclusion) in Patient-Reported Pain Scores on the Visual Analog Scale (VAS) to each visits
Time Frame: Week 3, Week 6, Month 6, Month 12, Month 24, Month 36, Month 48
|
Visual Analog Scale (VAS) is a unidimensional measure of pain intensity, used to record patients' pain progression.
It will helped the patient to assess the perceived mechanical knee pain on a horizontal, non-calibrated line of 10 cm, ranging from very low (0) to very high (10).
|
Week 3, Week 6, Month 6, Month 12, Month 24, Month 36, Month 48
|
Change from baseline (inclusion) in International Knee Documentation Committee (IKDC) score to each visits
Time Frame: Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
IKDC is a subjective knee evaluation form to detect improvement or deterioration in symptoms, function and sports activities due to knee impairment. This self-questionnaire is divided into three parts (symptoms, sports activities, function) and gives a score between 0 (worst) and 100 (best). |
Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
Change from baseline (inclusion) for the Knee injury and Osteoarthritis Outcome Score (KOOS) to each visits
Time Frame: Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
KOOS is a knee-specific instrument, developed to assess the patient's opinion about their knee and associated problems. The KOOS evaluates both short-term and long-term consequences of knee injury. It contains 42 items divided into five subscales: KOOS Pain, KOOS Symptoms, Activities of Daily Living (KOOS ADL), Sport (KOOS Sport), and Quality of Life regarding the knee (KOOS QOL). Total scores can range from 0 to 100. |
Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
Rate of adverse events
Time Frame: Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
To assess the rate of adverse events
|
Week 3, Week 6, Month 3, Month 6, Month 12, Month 24, Month 36, Month 48
|
Radiography and MRI evolution of the knee lesions from baseline (inclusion) to 24 months
Time Frame: Month 24
|
Morphologic evolution of knee joint on MRI and radiography
|
Month 24
|
Rate of conversion to prosthetic replacement
Time Frame: Month 12, Month 24, Month 36, Month 48
|
Rate of patient who have to undergo to prosthetic replacement
|
Month 12, Month 24, Month 36, Month 48
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Subchondroplasty
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on AccuFill® Porous Bone Substitute Material (BSM)
-
Institut Straumann AGTerminatedTooth LossUnited States
-
Assistance Publique - Hôpitaux de ParisGeistlich Pharma AGUnknownBone | Alveolar Bone Loss | Bone Substitute | Denture Complete Immediate | Replacement MaterialFrance
-
Göteborg UniversityKing's College London; Charite University, Berlin, Germany; Geistlich Pharma AG; Queen Mary University of London and other collaboratorsNot yet recruitingPeriodontitis | Furcation DefectsSweden
-
Alexandria UniversityUnknown
-
Seoul National University HospitalUnknownOsteoarthritis, KneeKorea, Republic of
-
University of North Carolina, Chapel HillGeistlich Pharma AGCompletedTooth ExtractionUnited States
-
University GhentCompletedExtensively Decayed Primary MolarsBelgium
-
Orton Orthopaedic HospitalTampere University; Biomendex Oy; Oral Hammaslääkärit Oy, Qmedical Pikku HuopalahtiTerminated
-
Medical University of GrazNot yet recruiting
-
Reham Lotfy AggourOctober 6 UniversityCompleted